Press Releases
Oct 19, 2020
VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid Tumors
Sep 08, 2020
VelosBio Appoints Paul Bavier as General Counsel
Aug 31, 2020
VelosBio Announces FDA Fast Track and Orphan Drug Designations for VLS-101 in Patients with Mantle Cell Lymphoma
Aug 03, 2020
VelosBio Appoints Dr. Enoch Kariuki as Chief Financial Officer
Jul 08, 2020
VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology
Now Leaving The VelosBio Site.
VelosBio Inc. is now a wholly-owned subsidiary of Merck & Co., Inc. (Kenilworth, New Jersey USA)